Targeted antibody ventures Mersana and CytomX attract venture dollars amid partnering promise
This article was originally published in Scrip
Companies on opposite US coasts announced venture capital funding on 31 July to boost next-generation targeted discovery and development platforms. Cambridge, Massachusetts-based antibody-drug conjugate (ADC) specialist Mersana Therapeutics raised $27 million in a Series A-1 round and CytomX Therapeutics in San Francisco increased its Series B round to $41 million for its tissue-specific antibodies.
You may also be interested in...
During a month when only two biotechnology companies have gone public, private drug developers continue to raise hundreds of millions of dollars in venture capital.
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.
The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year.